Aktis Oncology, Inc. Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations
Aktis Oncology, Inc. (AKTS) reported Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations of $44.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations · last filed 2026-08-13
- Aktis Oncology, Inc. cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect continuing operations for the quarter ending 2026-03-31 was $333.85M, a 1482.88% increase year-over-year.
- Aktis Oncology, Inc. cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect continuing operations for the quarter ending 2025-03-31 was $21.09M.
| Period end | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations 3 month | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations 6 month |
|---|---|---|
| 2026-06-30 | $44.71M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $333.85M 10-Q · filed 2026-05-11 | |
| 2025-06-30 | $73.06M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $21.09M 10-Q · filed 2026-05-11 |